A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
|Articles|September 23, 2019
Prostate Cancer Awareness Month: What You Need to Know
Author(s)Jessica Skarzynski
For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
Advertisement
For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space:
- Following the Food and Drug Administration’s recent approval of Nubeqa (darolutamide), men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.
- Newly diagnosed? This piece gathers the best advice about prostate cancer from the men and families who have already gone through it.
- Men with advanced prostate cancer may benefit from genomic testing as BRCA and other gene mutations play a bigger role in guiding treatment.
- After taking up running at age 63, Andy Steinfeldt was diagnosed with prostate cancer a few years later. But he didn’t let it slow him down. Listen to our podcast interview with Andy, who looks at cancer “as a motivation rather than a destination."
- The Prostate Cancer Foundation recently announced a host of new free resources for patients and their families to ensure they can make the best treatment choices.
Advertisement
Related to this article
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.
After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).
For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.
After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.
Advertisement
Advertisement
Trending on CURE
1
5 Years of Pancreatic Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
3
The Breast Cancer Test Many Patients Don’t Know to Ask For
4
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
5